Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
Top Page
Crescent Biopharma
(NASDAQ:CBIO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$11.00
▲(0.27% Upside)
The score is held back primarily by persistent losses and heavy cash burn alongside a bearish technical trend. The main offset is balance-sheet strength with very low leverage and improved equity position, which reduces near-term solvency risk.
Crescent Biopharma (CBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$302.30M
Dividend YieldN/A
Average Volume (3M)145.41K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth-100.00%
EPS Growth-0.58%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.27
Shares Outstanding27,556,767
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio-24.58
Price to Book (P/B)-139.86
Price to Sales (P/S)0.00
P/FCF Ratio-51.61
Enterprise Value/Market Cap0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$28.20Price Target Upside157.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Crescent Biopharma Business Overview & Revenue Model
Company DescriptionCrescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
How the Company Makes MoneyGlycoMimetics generates revenue primarily through research and development collaborations, milestone payments, and licensing agreements with larger pharmaceutical companies. These partnerships provide funding and resources for the development of its drug candidates. The company may also receive royalties from the commercial sales of any successfully developed products. As GlycoMimetics is a clinical-stage company, it does not yet have products on the market and thus does not generate revenue from direct product sales. Instead, its financial performance depends heavily on its ability to secure and maintain strategic partnerships to advance its drug pipeline toward commercialization.
Crescent Biopharma Earnings Call Summary
Earnings Call Date:May 06, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.Q1-2024 Updates
Positive Updates
Low Discontinuation Rate
The study had a low discontinuation rate of 3%, indicating good patient retention and adherence to the trial protocol.
Rich Data Set for Future Analysis
The study involved 388 patients with an unprecedented follow-up of over 3 years, providing a rich data set for further analysis and potential insights into AML treatment.
Commitment to Further Research
Despite the trial's primary endpoint not being met, GlycoMimetics remains committed to exploring uproleselan's potential in AML and plans to conduct a rigorous analysis of the data.
Ongoing Trials and Future Plans
The National Cancer Institute is sponsoring an ongoing Phase II/III trial evaluating uproleselan in newly diagnosed older patients with AML, and results will be shared when available.
Negative Updates
Phase III Study Did Not Meet Primary Endpoint
The pivotal Phase III study of uproleselan did not achieve a statistically significant improvement in overall survival in the intent-to-treat population.
Unprecedented Control Group Survival
The control group showed a median overall survival of 12.3 months, which is unprecedented in relapsed/refractory AML trials, potentially affecting the study's outcomes.
Financial and Budgetary Concerns
The company is evaluating ways to reduce cash burn and is expected to report back to investors with a revised budget.
Company Guidance
During the Q1 2024 earnings call for GlycoMimetics, the management provided updates on the Phase III study of their lead drug candidate, uproleselan, which unfortunately did not achieve a statistically significant improvement in overall survival for patients with relapsed/refractory acute myeloid leukemia (AML). The trial involved 388 patients across 70 sites in 9 countries, with a median overall survival of 13 months for the uproleselan arm and 12.3 months for the placebo arm. Despite not meeting its primary endpoint, the study's unexpected control group survival rate of over one year is considered unprecedented in this setting. The company plans to conduct a comprehensive analysis of the data in collaboration with medical, statistical, and regulatory experts and intends to present findings at a future medical meeting. Additionally, GlycoMimetics highlighted ongoing studies, including a National Cancer Institute-sponsored Phase II/III trial, and mentioned efforts to manage cash burn and revise budget plans as they proceed with further analyses and discussions with the FDA.Crescent Biopharma Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 10.00K | 75.00K | 1.16M | 10.16M |
| Gross Profit | 0.00 | 0.00 | 10.00K | 75.00K | 1.16M | 10.16M |
| EBITDA | -53.01M | 0.00 | -39.12M | -47.20M | -63.18M | -51.24M |
| Net Income | -55.96M | -71.47M | -36.90M | -46.69M | -63.43M | -51.03M |
Balance Sheet | ||||||
| Total Assets | 138.27M | 35.62M | 45.32M | 51.81M | 94.35M | 142.83M |
| Cash, Cash Equivalents and Short-Term Investments | 133.26M | 34.77M | 41.79M | 47.87M | 90.25M | 137.04M |
| Total Debt | 1.74M | 37.48M | 808.40K | 918.55K | 1.92M | 2.82M |
| Total Liabilities | 21.63M | 51.10M | 6.90M | 8.88M | 12.74M | 14.61M |
| Stockholders Equity | 116.64M | -15.48M | 38.41M | 42.93M | 81.60M | 128.22M |
Cash Flow | ||||||
| Free Cash Flow | -49.22M | -31.11M | -34.90M | -46.54M | -57.50M | -39.31M |
| Operating Cash Flow | -48.49M | -31.10M | -34.88M | -46.46M | -57.49M | -39.24M |
| Investing Cash Flow | -696.00K | 20.03K | -21.39K | -84.19K | -14.94K | -68.51K |
| Financing Cash Flow | 144.12M | 5.40K | 28.82M | 4.16M | 10.72M | 18.14M |
Crescent Biopharma Technical Analysis
Negative
10.97
Price Trends
12.86
Negative
12.82
Negative
15.74
Negative
Market Momentum
-0.60
Positive
35.19
Neutral
12.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBIO, the sentiment is Negative. The current price of 10.97 is below the 20-day moving average (MA) of 12.33, below the 50-day MA of 12.86, and below the 200-day MA of 15.74, indicating a bearish trend. The MACD of -0.60 indicates Positive momentum. The RSI at 35.19 is Neutral, neither overbought nor oversold. The STOCH value of 12.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBIO.
Crescent Biopharma Risk Analysis
Crescent Biopharma disclosed 59 risk factors in its most recent earnings report. Crescent Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Crescent Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $273.29M | -2.66 | -166.97% | ― | 6.46% | -14.32% | |
53 Neutral | $287.79M | -0.92 | -518.40% | ― | -96.91% | 63.11% | |
52 Neutral | $153.40M | -5.48 | -52.95% | ― | -88.47% | -1658.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $122.27M | -0.80 | -52.35% | ― | -46.92% | 20.26% | |
46 Neutral | $302.30M | -0.50 | -51.70% | ― | -100.00% | -0.58% |
* Healthcare Sector Average
CBIO
Crescent Biopharma
10.97
-14.12
-56.28%
CGEN
Compugen
1.64
-0.35
-17.59%
FATE
Fate Therapeutics
1.06
-0.23
-17.83%
OBIO
Orchestra BioMed Holdings
4.84
-0.29
-5.65%
GUTS
Fractyl Health, Inc.
2.10
0.15
7.69%
ACTU
Actuate Therapeutics, Inc.
6.28
-1.80
-22.28%
Crescent Biopharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Crescent Biopharma Secures $185M Through Private Placement
Positive
Dec 4, 2025
On December 2, 2025, Crescent Biopharma entered into a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., involving two license agreements. Crescent granted Kelun-Biotech exclusive rights to develop and commercialize CR-001, a bispecific antibody, in Greater China, while Crescent received rights to develop SKB105, an integrin beta-6-directed ADC, outside Greater China. This collaboration is expected to enhance Crescent’s oncology pipeline and accelerate the development of combination therapies. Additionally, Crescent announced a private placement agreement on December 4, 2025, to raise approximately $185 million, which will fund its operations into 2028, supporting its strategic initiatives and clinical development programs.
The most recent analyst rating on (CBIO) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Crescent Biopharma stock, see the CBIO Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.